Strategy and support for financing, restructuring, divestitures and M&A initiatives to grow your business.
Venture Capital / Private Equity - Early Stage Science and Discovery Vehicle Collaboration between Bristol-Myers Squibb and Allied Minds to form Allied-Bristol Life Sciences LLC, an enterprise created to identify and foster research and pre-clinical development of biopharmaceutical innovations from leading university research institutions across the U.S. Allied Minds and Bristol-Myers Squibb together will form and fund new companies to conduct feasibility and full-phase discovery programs. Once a program succeeds in identifying a pre-clinical candidate, Bristol-Myers Squibb will have the option to acquire the company from Allied-Bristol Life Sciences LLC under pre-agreed terms. Role: Transaction Advisor Reporting to the CFO, responsible to evaluate and gain alignment on potential vehicle structures to share risk and expand access to research and development programs through financial partnering. Worked with transaction lead, legal and technical accounting to characterize, evaluate and make recommendations on various transaction and vehicle structures Presented various vehicle structures to gain alignment with senior management Authored presentations to gain Board approval of alternative R&D financing vehicle strategies
Private Equity Raised $6.3 M in Private Equity financing for NexGenix Pharmaceuticals. Role: Transaction Lead Reporting to the CEO, led the process for investment in a Series B round of private equity funding. Authored company materials and presented to Angel and Private Equity investors Authored prospectus Managed share transfer process and financial reporting requirements
Initial Public Offering $10 M Initial Public Offering for Adherex Technologies (TSX: AHX)
underwritten by a syndicate led by Canaccord Capital Corporation, and including Yorkton Securities Inc., TD Securities Inc. and Dlouhy Merchant Group Inc. Role: Transaction Team Member Reporting to the COO responsible for supporting financial, marketing and investor relations activities related to the IPO Authored key sections of the company prospectus related to scientific/medical rationale, drug development strategy, and operational capabilities Developed ‘Roadshow’ presentation materials Drafted securities filings for accounting/legal review and managed share transfer agent
Private Company Acquisition $725 M acquisition of iPierian, Inc., by Bristol-Myers Squbb. Structured acquisition with an up-front purchase price of $175 M, potential development and regulatory milestone payments of up to $550 million, and a unspecified royalty on future net sales. Role: Transaction Lead Reporting to the VP Business Development, responsible to lead organizational alignment and diligence team to successful acquisition. Drove analysis and strategic thinking to frame discussions around the firm’s priorities and translate strategic objectives into actionable deal criteria Managed deal comparables analysis, diligence process and management communications Participated in deal structuring, negotiation and legal contract review Obtained organizational alignment and authored materials for management briefings and Board approval
Public Company Acquisition with Co-Commercialization Partner $7 B acquisition of Amylin Pharmaceuticals (NASDAQ: AMLN), by Bristol-Myers Squibb. This innovative transaction included a collaboration arrangement with AstraZeneca to subsequently acquire 50% ownership of the newly acquired entity for $3.5 B. Role: Transaction Lead Reporting to the VP corporate development, responsible to lead organizational alignment and diligence team to successful acquisition. Managed diligence process and financial valuation Obtained organizational alignment and authored materials for management briefings and board approval for hostile acquisition offer and subsequent sale process Act as lead point of contact for external advisors, acquisition partner and internal diligence team Participated in deal structuring, negotiation and legal contract review Co-led negotiations for a definitive collaboration and co-commercialization agreement with AstraZeneca for the assets post-acquisiton
Divestiture of Latin American Over-the-Counter Medicine Brands Structured buy-out in the form of a three year license and supply agreement between Bristol-Myers Squibb and Reckitt Benckiser for a number of market-leading OTC brands in Latin America, with an option to purchase at the end of the three year period. Financial terms include a $482 M upfront payment, undisclosed royalties and an undisclosed purchase price. Role: Transaction Co-Lead Reporting to the VP corporate development, responsible to lead organizational alignment and diligence team to successful completion of the structured asset divestiture. Define divestiture scope related to assets, regions, and financial structure to align with BMS strategy Gain internal buy-in from key stakeholders including global organization executives, country managers and core OTC team Act as lead point of contact for external advisors and third parties Prepared ‘teaser’ materials, Confidential Information Memorandum and Management Presentations in an organized sale process Lead efforts of cross functional manufacturing, regulatory, commercial and operations diligence team Prepare executive briefs, talking points and board approval materials
Technology License and Collaborative Research Agreement HSP90 Inhibitor In-license from Universite Louis Pasteur, Strasbourg NexGenix Pharmaceuticals
. Exclusive Worldwide License to develop and commercialize a novel family of Hsp90 inhibitor and Collaborative Research Agreement to further expand the compound series in return for maintenance fees, milestone payments and royalties. Terms not disclosed. Role: Transaction Lead Reporting to the CEO, responsible to lead diligence and valuation efforts, ensure management and board alignment and negotiate transaction. Evaluation/Diligence Alignment with key internal stakeholders and board members Valuation analysis and term negotiation Contract negotiation
Spin-off and Merger Adherex Technologies spin-off of non-cancer assets into Cadherin Biomedical Research, Inc. and merger of equals with Oxiquant Inc., a private US pharmaceutical company into a combined company with a focus on anti-cancer therapeutics. Role: Transaction Lead Reporting to the CEO/COO responsible for coordinating diligence materials, advising upon terms, authoring supporting materials for the transaction and managing the shareholder approval process. Co-led diligence evaluation team (with Project Manager) Evaluated terms and participated in negotiations, prepared board discussion and shareholder approval materials